U.S. Markets close in 3 hrs 30 mins

Soligenix, Inc. (SNGX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.9733-0.0167 (-1.69%)
As of 12:26PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.9900
Bid0.9752 x 900
Ask0.9760 x 1100
Day's Range0.9700 - 0.9955
52 Week Range0.8600 - 2.9900
Avg. Volume740,915
Market Cap39.009M
Beta (5Y Monthly)1.31
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Soligenix Stock Plummets After It Announces Not To Pursue Rolling US Application Submission For HyBryte

    Soligenix Stock Plummets After It Announces Not To Pursue Rolling US Application Submission For HyBryte

    Soligenix Inc (NASDAQ: SNGX) shares dropped during premarket after the company said it would not pursue a rolling marketing application submission for HyBryte (SGX301). Instead, it plans to submit the NDA in the first half of 2022. The decision follows the company's discussions with the FDA regarding the HyBryte application submission. Based on the discussions and given delays in manufacturing, in part caused by the global COVID-19 pandemic, Soligenix has decided to drop the rolling NDA submission at this time to provide additional supportive data for inclusion in the NDA filing. The company sees potential FDA approval adjusted to the first half of 2023. Recently, confirmatory data from its Phase 3 FLASH study was presented at the Society for Investigative Dermatology (SID) Virtual Meeting. The presented data demonstrated the ability of HyBryte to treat both patch and plaque disease, including generating complete disease responses, while being associated with fewer and less severe adverse events than other currently approved skin-directed therapies for cutaneous T-cell lymphoma. HyBryte (SGX301 or synthetic hypericin) is a novel photodynamic therapy utilizing safe, visible light to treat cutaneous T-cell lymphoma. Price Action: SNGX shares fell 17.2% at $1.06 in the premarket trading on the last check Monday. See more from BenzingaClick here for options trades from BenzingaViatris Q1 Sales Tops Estimates, Reaffirms 2021 Outlook, Announces Quarterly DividendBioNTech Clocked Massive Q1 Revenue Growth; Estimates COVID-19 Vaccine Revenues Of €12B© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Soligenix, Inc.'s (NASDAQ:SNGX) Profit Outlook
    Simply Wall St.

    Soligenix, Inc.'s (NASDAQ:SNGX) Profit Outlook

    Soligenix, Inc. ( NASDAQ:SNGX ) is possibly approaching a major achievement in its business, so we would like to shine...

  • The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company

    The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 3) Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) Bausch Health Companies Inc. (NYSE: BHC) ENDRA Life Sciences Inc. (NASDAQ: NDRA) iTeos Therapeutics, Inc. (NASDAQ: ITOS) Magenta Therapeutics, Inc. (NASDAQ: MGTA) (reacted to fourth-quarter results) MiMedx Group, Inc. (NASDAQ: MDXG) Renalytix AI plc (NASDAQ: RNLX) Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 3) AbCellera Biologics Inc. (NASDAQ: ABCL) Athenex, Inc. (NASDAQ: ATNX) Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) Epizyme, Inc. (NASDAQ: EPZM) Freeline Therapeutics Holdings plc (NASDAQ: FRLN) Galecto, Inc. (NASDAQ: GLTO) Inhibikase Therapeutics, Inc. (NASDAQ: IKT) Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) Karyopharm Therapeutics Inc (NASDAQ: KPTI) Lucira Health Inc (NASDAQ: LHDX) Protara Therapeutics, Inc. (NASDAQ: TARA) Sana Biotechnology, Inc. (NASDAQ: SANA) Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) Talis Biomedical Corporation (NASDAQ: TLIS) Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) Virios Therapeutics, LLC (NASDAQ: VIRI) Voyager Therapeutics, Inc. (NASDAQ: VYGR) Stocks In Focus Kiniksa's UK Subsidiary Executes Rilonacept Commercialization Agreement With Regeneron Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) said its U.K. subsidiary Kiniksa U.K. has entered into a commercial supply agreement with Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), under which Regeneron has the exclusive right to manufacture and supply rilonacept for Kiniksa U.K.'s requirements. The agreement follows Kiniksa executing an asset transfer agreement to Kiniksa U.K. in January. Kiniksa has a 2017 licensing agreement with Regeneron for the supply of rilonacept. Kiniksa shares gained 10.34% to $24 in after-hours trading. Pfizer Gets Label Expansion For Blood Cancer Drug Pfizer Inc. (NASDAQ: PFE) announced FDA approval for its supplemental biologics license application for Lorbrena, with the latest approval expanding the indication to include first-line treatment of people with anaplastic lymphoma kinase non-small cell lung cancer. Lorbrena has already been approved for adults with metastatic NSCLC whose tumors are ALK-positive as detected by an FDA-approved test. Regeneron-Sanofi Submit Regulatory Application For Dupixent Label Expansion Sanofi (NASDAQ: SNY) and Regeneron said the FDA has accepted the sBLA for Dupixent for review as an add-on treatment for children ages 6-11 with uncontrolled moderate-to-severe asthma. Dupixent is approved as an add-on treatment for patients with uncontrolled moderate-to-severe asthma ages 12 and older with elevated eosinophils or oral corticosteroid-dependent asthma. The target action date for the FDA decision is Oct. 21. The companies said EU regulatory submission for children ages 6-11 years with asthma is planned for the first quarter of 2021. Lilly's Type 2 Diabetes Drug Aces Late-Stage Study Eli Lilly and Company (NYSE: LLY) announced topline results from the Phase 3 SURPASS study showing that trizepatide led to superior A1C and body weight reductions from baseline across all three doses compared to injectable semaglutide 1 mg in adults with type 2 diabetes. The stock was up 0.37% to $202.75 in premarket trading Thursday. Related Link: The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earning Kronos Bio To Proceed With Registrational Late-Stage Blood Cancer Study Following Positive End-Of-Phase 2 Meeting With FDA Kronos Bio, Inc. (NASDAQ: KRON) said following receipt of minutes from its end-of-Phase 2 meeting with the FDA, it will proceed with its plan to assess measurable residual disease negative complete response as the primary endpoint in a registrational Phase 3 trial to support potential accelerated approval of entospletinib in patients newly diagnosed with NPM1-mutated acute myeloid leukemia. View more earnings on IBB The company plans to initiate the Phase 3 trial in mid-2021, with MRD negative CR data expected in the second half of 2023. Soligenix Announces Positive Preclinical Data For Heat-Stable COVID-19 Vaccine Program Soligenix, Inc. (NASDAQ: SNGX) announced publication of data from preclinical immunogenicity studies for CiVax, its heat stable COVID-19 vaccine program, demonstrating rapid-onset, broad-spectrum, neutralizing antibody and cell-mediated activity. The company said it will continue the study under a $1.5-million Small Business Innovation Research grant awarded to it in December. The stock was jumping 13.04% to $1.82 in premarket trading Thursday. Luminex Gets Authorization For An Expanded Version of Respiratory Pathogen Panel Luminex Corporation (NASDAQ: LMNX) announced that it has received emergency use authorization from the FDA for a new expanded version of its NxTAG Respiratory Pathogen Panel that includes the SARS-CoV-2 virus for high-throughput respiratory testing. The new test is a combination of the company's original NxTAG RPP, an FDA-cleared in vitro diagnostic for syndromic respiratory infection testing and SARS-CoV-2. Bio-Techne To Buy Texas-Based Cancer Diagnostics Company Asuragen For Up To $320M Bio-Techne Corporation (NASDAQ: TECH) announced it has reached an agreement to acquire Austin, Texas-based Asuragen for an initial consideration of $215 million in cash, plus contingent consideration of up to $105 million upon the achievement of certain future milestones. Asuragen develops and commercializes genetic carrier screening and oncology testing kits. Bio-Techne anticipates the acquisition to close in the fourth quarter of its fiscal 2021. Clearside Biomedical Gains On Insider Transactions Clearside Biomedical, Inc.'s (NASDAQ: CLSD) chief medical officer Thomas Ciulla purchased 40,000 shares through the vesting of employee stock options. Meanwhile, CEO George Lasezkay sold 6,000 shares at $3.37 per share. Subsequent to the sale, Lasezkay beneficially owned 433,609 shares in the company. The stock rose 13.70% to $3.90 in after-hours trading. Galapagos Reports Interim Safety Results From Studies In Male Patients With Rheumatoid Arthritis, Inflammatory Bowel Disease Galapagos NV (NASDAQ: GLPG) announced interim safety results from Phase 2 MANTA and MANTA-Ray studies investigating the effect of filgotinib on sperm parameters in males with inflammatory bowel disease or rheumatic conditions, showing 8.3% patients on placebo and 6.7% patients on filgotinib had a 50% or more decline in sperm concentration at week 13. No new safety findings were identified, the companies added. These studies are not powered for statistical comparison between groups and the data will now be submitted to relevant regulatory authorities, Galapagos said. Earnings Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) said the FDA has requested to expand the company's intravenous and inhalation and COVID-19 studies, using Ampion, by conducting a Phase 2 trial for each. The agency indicated Ampion may be considered for emergency use authorization, and that the recommended trial design for both trials will help determine the safety and statistical significance and effectiveness of Ampion in comparison to standard-of-care. The company also reported its financial results, showing a narrower loss of 9 cents per share for the fiscal year 2020 compared to a loss of 14 cents per share a year earlier. Cash and cash equivalents totaled $17.3 million at Dec. 31, 2020, compared to $6.5 million at Dec. 31, 2019. The stock was up 9.79% to $1.57 in after-hours trading. Earnings Arbutus Biopharma Corp (NASDAQ: ABUS) (before the market open) Fulcrum Therapeutics, Inc. (NASDAQ: FULC) (before the market open) X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) (before the market open) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) (before the market open) X4 Pharmaceuticals Inc (NASDAQ: XFOR) (before the market open) Syros Pharmaceuticals Inc (NASDAQ: SYRS) (before the market open) Opiant Pharmaceuticals Inc (NASDAQ: OPNT) (after the close) Acorda Therapeutics Inc (NASDAQ: ACOR) (after the close) Anika Therapeutics Inc (NASDAQ: ANIK) (after the close) INmune Bio Inc (NASDAQ: INMB) (after the close) Synthetic Biologics Inc (NYSE SYN) (after the close) T2 Biosystems Inc (NASDAQ: TTOO) (after the close) Evofem Biosciences Inc (NASDAQ: EVFM) (after the close) DermTech Inc (NASDAQ: DMTK) (after the close) Chiasma Inc (NASDAQ: CHMA) (after the close) Clearpoint Neuro Inc (NASDAQ: CLPT) (after the close) Fulgent Genetics, Inc. (NASDAQ: FLGT) (after the close) Related Link: Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates See more from BenzingaClick here for options trades from BenzingaThe Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine StudyThe Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.